"Creation of the
Members of the
-
Greg Elliot , M.D., MACP, Medical Director of the Pulmonary Hypertension Center and Chairman of theDepartment of Medicine atIntermountain Medical Center and Professor of Medicine at theUniversity of Utah -
Nazzareno Galie , M.D., Head of the Pulmonary Hypertension Center at theUniversity of Bologna -
Ardeschir Ghofrani, M.D., Associate Professor for Internal Medicine and Head of the Pulmonary Hypertension Division at
University Hospital ,Giessen -
Fernando Martinez , M.D., Executive Vice Chair of Medicine at theWeill Cornell Medical College andNew York-Presbyterian Hospital/Weill Cornell Medical Center -
Vallerie McLaughlin , M.D., Professor of Medicine and Director of the Pulmonary Hypertension Program at theUniversity of Michigan ; Attending Physician at theUniversity of Michigan Health System inAnn Arbor, Michigan -
Robert Naeije, M.D., Ph.D, Professor and Chairman of the
Department of Physiology and Pathophysiology atErasme University Hospital ,Brussels -
Steve Rennard , M.D., Larson Professor of Medicine in the Pulmonary and Critical Care Medicine,Department of Internal Medicine at theUniversity of Nebraska Medical Center inOmaha -
Lewis Rubin , M.D., FACP, FCCP, FAHA, FRCP, Emeritus Professor of Medicine and Emeritus Director of Pulmonary and Critical Care at theUniversity of California in San Diego -
Olivier Sitbon , M.D., Ph.D., Professor of Respiratory Medicine at theSouth Paris University
About INOpulse
INOpulse is Bellerophon's proprietary pulsatile nitric oxide drug-device combination technology for the treatment of pulmonary hypertension in the chronic outpatient setting. Two of the Company's programs using this technology are currently in development – one for the treatment of PAH is expected to begin Phase 3 trials later this year, and a second for the treatment of PH-COPD is being evaluated for a Phase 2b trial.
Nitric oxide is naturally produced and released by portions of the blood vessels and results in smooth muscle relaxation. In particular, nitric oxide controls muscle tone in blood vessels and, thus, is an important factor in regulating blood pressure. As the muscles of the blood vessels relax, blood flow increases, helping the heart to deliver more blood to the body.
About Bellerophon
Forward-looking Statements
Any statements in this press release about Bellerophon's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent Bellerophon's views only as of the date of this press release. Bellerophon anticipates that subsequent events and developments will cause its views to change. While Bellerophon may elect to update these forward-looking statements at some point in the future, Bellerophon specifically disclaims any obligation to do so.
CONTACT: At Bellerophon:Manesh Naidu , Chief Business Officer (908) 574-4770At Rx Communications Group :Paula Schwartz (Investors) (917) 322-2216Eric Goldman (Media) (917) 322-2563 egoldman@RxIR.com